Replimune Group, Inc. announced the appointment of Christopher Sarchi as company's Chief Commercial Officer and the appointment of Sushil Patel, Ph.D., previously company's Chief Commercial Officer, to a newly created position of Chief Strategy Officer, effective immediately. Chris brings more than 28 years of oncology experience, including 9 new product launches/expansions covering multiple tumor types and settings while building strong relationships with oncology physicians, nurses and pharmacy leaders throughout the oncology market. Chris joins Replimune having recently served as Head of Commercial U.S. Oncology at Sanofi where he was responsible for several launches, including the launch of Libtayo® as a new standard of care treatment for CSCC.

Prior to heading the U.S. commercial oncology team at Sanofi, Chris was Vice President and Business Unit Head, Oncology and Biosimilars, at Boehringer Ingelheim, Inc. after serving as a commercial leader within the oral oncolytic franchise at Roche/Genentech where he launched Erivedge® in basal cell carcinoma and coordinated internal co-promotion of Tarceva® and Avastin®. Chris began his career with GSK where he held several sales and marketing leadership roles of increasing responsibility. Chris received a Bachelor of Science and Business Administration from the University of Maine.

Sush most recently served as Replimune's Chief Commercial Officer. Prior to joining Replimune in 2021, Sushil served as Franchise Head in Global Product Strategy for Genentech, a member of the Roche Group, where he was responsible for directing the company's lung and skin cancer franchise with responsibility for multiple blockbuster drugs, generating in excess of $3.5 billion in annual global sales. Prior to his career in biotechnology, he worked as a strategic management consultant and at IMS Health in their Pharma Strategy Group.

Sushil received a Doctor of Philosophy in Molecular Biology and a Master of Sciences in Biotechnology, both from the Imperial College of Science Technology and Medicine, University of London.